A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD

Exclusion Criteria

• •Presence of active or inactive CNV in the eye to be treated.
• •Presence or history of retinal dystrophy, retinitis pigmentosa, chorioretinitis, central serious choroidopathy, diabetic retinopathy or other retinal vascular or degenerative disease other than ARMD.
• •History of optic neuropathy.
• •Macular atrophy due to causes other than AMD.
• •Presence of glaucomatous optic neuropathy in the study eye, uncontrolled IOP, or use of two or more agents to control IOP (acetazolamide, beta blocker, alpha-1-agonist, prostaglandins, anhydrous carbonic inhibitors)
• •Cataract of sufficient severity likely to necessitate surgical extraction within 1 year.
• •History of retinal detachment repair in the study eye.
• •History of myocardial infarction in previous 12 months.
• •History of diabetes mellitus.
• •History of cognitive impairments or dementia which may impact the patients ability participate in the informed consent process and to appropriately complete evaluations.
• •Any immunodeficiency.
• •Any abnormalities in laboratory test result.
• •Serologic evidence of infection with Hepatitis B, Hepatitis C, or HIV.
• •Current participation in any other clinical trial.
• •Participation within previous 6 months in any clinical trial of a drug by ocular or systemic administration.
• •Any other sight-threatening ocular disease.
• •Ocular lens removal within previous 3 months.
• •Ocular surgery in the study eye in the previous 3 months
• •If female, pregnancy or lactation.
• •Any other medical condition, which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromises patient safety, or interferes with the interpretation of the study results.